Clinical significance of quantitative categorization of HER2 fluorescent in situ hybridization results in invasive breast cancer patients treated with HER2-targeted agents.

MLA

Alhamar, Mohamed, et al. “Clinical Significance of Quantitative Categorization of HER2 Fluorescent in Situ Hybridization Results in Invasive Breast Cancer Patients Treated with HER2-Targeted Agents.” Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc, vol. 34, no. 4, Apr. 2021, pp. 720–34. EBSCOhost, https://doi.org/10.1038/s41379-020-00728-z.

APA

Alhamar, M., Alkamachi, B., Mehrotra, H., Sanchez, J., Ali, H., Schultz, D., & Chitale, D. A. (2021). Clinical significance of quantitative categorization of HER2 fluorescent in situ hybridization results in invasive breast cancer patients treated with HER2-targeted agents. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc, 34(4), 720–734. https://doi.org/10.1038/s41379-020-00728-z

Chicago

Alhamar, Mohamed, Bassam Alkamachi, Harshita Mehrotra, Jessica Sanchez, Haythem Ali, Daniel Schultz, and Dhananjay A Chitale. 2021. “Clinical Significance of Quantitative Categorization of HER2 Fluorescent in Situ Hybridization Results in Invasive Breast Cancer Patients Treated with HER2-Targeted Agents.” Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc 34 (4): 720–34. doi:10.1038/s41379-020-00728-z.